REPL

9.75

6.16% -0.64

Handel nachbörslich: 9.75

Replimune Group Inc (REPL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$10.39

Offen:

$10.02

24-Stunden-Volumen:

913.43K

Relative Volume:

1.36

Marktkapitalisierung:

$851.01M

Einnahmen:

Nettoeinkommen (Verlust:

$-209.96M

KGV:

-3.0854

EPS:

-3.16

Netto-Cashflow:

$-176.27M

1W Leistung:

-11.76%

1M Leistung:

-23.11%

6M Leistung:

-11.04%

1J Leistung:

+19.34%

1-Tages-Spanne:

$9.58

$10.19

1-Wochen-Bereich:

$9.58

$11.22

52-Wochen-Spanne:

$4.92

$17.00

Replimune Group Inc Stock (REPL) Company Profile

Firmenname

Replimune Group Inc

Sektor

Healthcare (1164)

Branche

Biotechnology (681)

Telefon

(781) 222-9600

Adresse

500 UNICORN PARK, WOBURN, MA

Mitarbeiter

Twitter

@Replimune

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

REPL's Discussions on Twitter

Vergleichen Sie REPL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REPL Replimune Group Inc	9.75	851.01M	0	-209.96M	-176.27M	-3.16
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-28	Eingeleitet	ROTH MKM	Buy
2023-04-17	Fortgesetzt	Piper Sandler	Overweight
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-10-15	Fortgesetzt	BTIG Research	Buy
2020-11-17	Eingeleitet	BTIG Research	Buy
2020-11-02	Eingeleitet	Jefferies	Buy
2020-10-15	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-07-01	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-05-05	Eingeleitet	Barclays	Overweight
2019-09-04	Eingeleitet	ROTH Capital	Buy
2019-07-23	Eingeleitet	Chardan Capital Markets	Buy
2019-07-12	Hochstufung	JP Morgan	Neutral → Overweight
2019-07-08	Eingeleitet	H.C. Wainwright	Buy
2019-04-25	Eingeleitet	Wedbush	Outperform
2019-01-23	Herabstufung	JP Morgan	Overweight → Neutral
2018-08-14	Eingeleitet	JP Morgan	Overweight
2018-08-14	Eingeleitet	Leerink Partners	Outperform

Alle ansehen

Replimune Group Inc Aktie (REPL) Neueste Nachrichten

Mar 30, 2025

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Swiss National Bank - Defense World

Mar 30, 2025

Mar 25, 2025

Charles Schwab Investment Management Inc. Has $6.16 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 25, 2025

Mar 22, 2025

Victory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 22, 2025

Bank of New York Mellon Corp Increases Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 22, 2025

Mar 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Holdings Cut by AlphaQuest LLC - Defense World

Mar 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Average Price Target from Analysts - Defense World

Mar 20, 2025

Mar 17, 2025

Arizona State Retirement System Invests $156,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 17, 2025

Mar 12, 2025

Financial Metrics Check: Replimune Group Inc (REPL)’s Ratios for Trailing Twelve Months - The Dwinnex

Mar 12, 2025

Mar 07, 2025

Replimune Group Appoints New Director, Grants Stock Options By Investing.com - Investing.com Australia

Mar 07, 2025

Replimune Group Appoints New Director, Grants Stock Options - Investing.com

Mar 07, 2025

Replimune Group Appoints Michael Goller To Board, Increases Board Size To Ten -March 07, 2025 at 05:04 pm EST - Marketscreener.com

Mar 07, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 07, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -March 07, 2025 at 04:11 pm EST - Marketscreener.com

Mar 07, 2025

Mar 06, 2025

Rhumbline Advisers Grows Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 06, 2025

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital

Mar 06, 2025

Mar 05, 2025

New York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 05, 2025

Mar 01, 2025

JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat

Mar 01, 2025

Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World

Mar 01, 2025

Feb 24, 2025

Replimune Group (NASDAQ:REPL) Stock Price Up 6.1%What's Next? - MarketBeat

Feb 24, 2025

Feb 23, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from Brokerages - Defense World

Feb 23, 2025

Feb 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Feb 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update - MarketBeat

Feb 20, 2025

Feb 18, 2025

Replimune's SWOT analysis: oncolytic immunotherapy stock poised for FDA approval - Investing.com

Feb 18, 2025

Feb 17, 2025

Possible Bearish Signals With Replimune Group Insiders Disposing Stock - Simply Wall St

Feb 17, 2025

HC Wainwright Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat

Feb 16, 2025

Feb 14, 2025

Replimune stock target raised to $22 at H.C. Wainwright - MSN

Feb 14, 2025

Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks - MSN

Feb 14, 2025

Feb 13, 2025

Replimune stock target raised to $22 at H.C. Wainwright By Investing.com - Investing.com Australia

Feb 13, 2025

Feb 12, 2025

Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL) - Seeking Alpha

Feb 12, 2025

Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating - Marketscreener.com

Feb 12, 2025